BPG is committed to discovery and dissemination of knowledge
Featured Articles
9/12/2019 10:05:43 AM | Browse: 222 | Download: 149
Publication Name World Journal of Meta-Analysis
Manuscript ID 49567
Country/Territory United States
2019-06-18 06:55
Peer-Review Started
2019-06-21 10:26
To Make the First Decision
2019-08-08 09:27
Return for Revision
2019-08-09 00:45
2019-08-15 14:57
Second Decision
2019-08-16 12:30
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2019-08-20 03:59
Articles in Press
2019-08-20 03:59
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2019-08-27 07:41
Publish the Manuscript Online
2019-09-03 07:56
ISSN 2308-3840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology and Hepatology
Manuscript Type Editorial
Article Title Tofacitinib for the treatment of ulcerative colitis: A review of the literature
Manuscript Source Invited Manuscript
All Author List Jessica Rosenberg, Joshua M Steinberg and Mark C Mattar
Funding Agency and Grant Number
Corresponding author Mark C Mattar, FACG, MD, Academic Research, Associate Professor, Department of Gastroenterology, MedStar Georgetown University Hospital, 3800 Reservoir Road NW, Washington, DC20007, United States. Mark.c.mattar@gunet.georgetown.edu
Keywords Ulcerative colitis; Tofacitinib; Review; Inflammatory bowel disease; Treatment;
Core Tip Tofacitinib is a small molecule that is an inhibitor of the Janus kinase signal transduction pathway, and it is the first oral medication approved for chronic use among adults with moderately to severely active ulcerative colitis (UC). Three large phase III trials have shown overall efficacy and safety; however, long-term results and real-world data are lacking in the literature. Our objective is it consolidate the current literature to better understand what is currently known about efficacy, safety, quality of life, and real-world experience with this medication among patients with UC.
Publish Date 2019-09-03 07:56
Citation Rosenberg J, Steinberg JM, Mattar MC. Tofacitinib for the treatment of ulcerative colitis: A review of the literature. World J Meta-Anal 2019; 7(8): 373-379
Url https://www.wjgnet.com/2308-3840/full/v7/i8/373.htm
DOI https://dx.doi.org/10.13105/wjma.v7.i8.373
Full Article (PDF) WJMA-7-373.pdf
Full Article (Word) WJMA-7-373.docx
Manuscript File 49567-Review.docx
Answering Reviewers 49567-Answering reviewers.pdf
Audio Core Tip 49567-Audio core tip.m4a
Conflict-of-Interest Disclosure Form 49567-Conflict-of-interest statement.pdf
Copyright License Agreement 49567-Copyright license agreement.pdf
Peer-review Report 49567-Peer-review(s).pdf
Scientific Misconduct Check 49567-Scientific misconduct check.pdf
Scientific Editor Work List 49567-Scientific editor work list.pdf